PAP
MAZE

Persistent Asset Partners’s Maze Therapeutics MAZE Stock Holding History

Persistent Asset Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Sell
6,709
-2,059
-23% -$54K 0.06% 214
2026
Q1 		$262K Buy
8,768
+2,163
+33% +$95.5K 0.1% 165
2025
Q4 		$274K Buy
+6,605
New +$227K 0.12% 191

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Persistent Asset Partners's MAZE Position: Q2 2026 in Review

Persistent Asset Partners reduced its Maze Therapeutics (MAZE) stake by 23% in Q2 2026, selling an estimated $54K and leaving 6,709 shares worth $200K. The position accounts for 0.06% of the portfolio, ranked #214.

Persistent Asset Partners first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $274K in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Persistent Asset Partners held 6,709 shares of Maze Therapeutics worth $200K as of Q2 2026.
  • Persistent Asset Partners sold 2,059 Maze Therapeutics shares in Q2 2026, an estimated $54K.
  • Maze Therapeutics made up 0.06% of Persistent Asset Partners's portfolio in Q2 2026, its #214 holding.
  • Persistent Asset Partners first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Maze Therapeutics position peaked at $274K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.